NSGO/AVANOVA

Trial Description: 
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Lead Cooperative Group: 
Disease Site: 
Ovarian
Trial Status: 
Completed
Contact person: